MYGN实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (29 Jun 2024 @ 04:00):
Our systems believe the stock currently is overvalued by -0.08% compare to its pairs and should correct downwards.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally...

Stats
今日成交量	1.37M
平均成交量	761 243
市值	2.21B
EPS	$-0.750 ( Q3 \| 2023-11-07 )
下一个收益日期	( $-0.0100 ) 2024-08-01
Last Dividend	$1.750 ( 2009-07-01 )
Next Dividend	$0 ( N/A )
P/E	-8.74 (Sector) 42.63 (Industry) 0
ATR14	$0.0180 (0.07%)

ACRS -0.90%

AKU -17.87%

APDN -0.73%

BDSX 2.00%

BIOC 0.00%

BNGO -7.69%

BNR 1.05%

CDNA 7.92%

CEMI 0.22%

CHEK -0.99%

CNTG -3.80%

CSTL 2.88%

DMTK -11.32%

DRIO 1.71%

EXAS -5.03%

FLDM -7.02%

FLGT -2.39%

GENE 1.35%

GH -0.59%

GTH 0.12%

HTGM 0.00%

ICLR 0.08%

IDXX -1.37%

ILMN -1.95%

ISPC -1.87%

LAB 0.00%

LMDX 0.00%

MDXH 0.84%

ME -7.58%

MEDP -2.94%

MYGN 0.62%

MYNZ -14.13%

NDRA -5.73%

NEO 3.97%

NEOG -2.07%

NOTV -4.05%

NTRA -1.56%

OCDX 0.92%

OLK 0.75%

OPGN 0.39%

OPK -0.79%

PMD 2.11%

PRPO 4.85%

PSNL -3.31%

RDNT 0.03%

SERA 3.50%

SHC -0.25%

SQL 0.00%

STIM -1.10%

STRR 2.71%

STRRP 8.67%

SYNH 0.02%

TRIB 2.90%

TTOO -1.66%

TWST 3.79%

VIVO 0.00%

XGN -1.62%

Insider Trading

Date	Person	Action	Amount	type
2024-06-06	Skovronsky Daniel	Buy	15 695	Common Stock
2024-06-06	Dreismann Heinrich	Buy	15 695	Common Stock
2024-06-06	Newcomer Lee Nisley	Buy	15 695	Common Stock
2024-06-06	Kumar Rashmi	Buy	15 695	Common Stock
2024-06-06	Reitan Colleen F	Buy	15 695	Common Stock

INSIDER POWER
35.27
Last 95 transactions
Buy: 1 228 148 \| Sell: 580 773

相关性 (AI algo v.1.1b): Overvalued: -0.08% $24.46 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

音量相关性

長: 0.51 (weak)

短: -0.36 (neutral)

Signal:(61.8) Neutral

Myriad Genetics Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Myriad Genetics Inc 相关性 - 货币/商品

-0.23
( neutral )

-0.35
( neutral )

0.00
( neutral )

0.26
( neutral )

0.00
( neutral )

0.43
( neutral )

Myriad Genetics Inc 财务报表

Annual	2022
营收:	$678.40M
毛利润:	$476.40M (70.22 %)
EPS:	$-1.390

FY	2022
营收:	$678.40M
毛利润:	$476.40M (70.22 %)
EPS:	$-1.390

FY	2021
营收:	$690.60M
毛利润:	$493.00M (71.39 %)
EPS:	$-0.350

FY	2020
营收:	$638.60M
毛利润:	$452.50M (70.86 %)
EPS:	$-2.69

Financial Reports:

No articles found.

Myriad Genetics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Myriad Genetics Inc Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$1.750	2009-06-15
Last Dividend	$1.750	2009-07-01
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$3.50	--
Avg. Dividend % Per Year	0.00%	--
Score	2.02	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-09-11)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

2.02

Pay Frequency

Monthly

Yearly Payout

Year	Amount	Yield
2009	$3.50	10.20%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
01 Jul 2009	$1.750	30 Nov -0001	30 Nov -0001	30 Nov -0001
15 Jun 2009	$1.750	30 Nov -0001	30 Nov -0001	30 Nov -0001

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Diamond	2024-09-16	Monthly	14	15.03%	9.60
DMLP	Dividend Diamond	2024-04-26	Quarterly	22	10.71%	9.35
OXSQ	Dividend Diamond	2024-09-16	Monthly	21	12.73%	9.02
ARLP	Dividend Royal	2024-05-07	Quarterly	26	9.67%	8.87
PNNT	Dividend Royal	2024-06-14	Monthly	18	9.49%	8.82
MFIC	Dividend Royal	2024-06-11	Quarterly	21	10.89%	8.79
SPOK	Dividend Royal	2024-05-23	Quarterly	20	8.73%	8.72
PSEC	Dividend Royal	2024-06-25	Monthly	21	9.03%	8.65
SBLK	Dividend Royal	2024-06-06	Quarterly	17	13.10%	8.63
GBDC	Dividend Royal	2024-11-29	Bi-Monthly	15	8.53%	8.62

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.374	1.500	-7.47	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.239	1.200	-7.96	-9.55	[0 - 0.3]
returnOnEquityTTM	-0.350	1.500	-5.00	-7.49	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.268	0.800	8.66	6.93	[1 - 3]
quickRatioTTM	0.963	0.800	9.04	7.23	[0.8 - 2.5]
cashRatioTTM	0.363	1.500	9.09	10.00	[0.2 - 2]
debtRatioTTM	0.175	-1.500	7.08	-10.00	[0 - 0.6]
interestCoverageTTM	-93.79	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.782	2.00	-0.261	-0.521	[0 - 30]
freeCashFlowPerShareTTM	-1.692	2.00	-0.846	-1.692	[0 - 20]
debtEquityRatioTTM	0.295	-1.500	8.82	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.689	1.000	1.852	1.852	[0.2 - 0.8]
operatingProfitMarginTTM	-0.370	1.000	-9.41	-9.41	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.317	1.000	-2.87	-2.87	[0.2 - 2]
assetTurnoverTTM	0.639	0.800	9.07	7.26	[0.5 - 2]
Total Score				-0.0149

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-7.29	1.000	-0.837	0	[1 - 100]
returnOnEquityTTM	-0.350	2.50	-3.21	-7.49	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.692	2.00	-0.564	-1.692	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.782	2.00	-0.261	-0.521	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.389	1.500	-5.92	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.0870	1.000	-4.68	0	[0.1 - 0.5]
Total Score				-2.41

Myriad Genetics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.